Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NEAL D BHATIA

Allopathic & Osteopathic Physicians Dermatology

NPI
1255349288
CMS profile
11650
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$588,420.94

657 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 14; records 51–100 of 657 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NEAL D BHATIA

NPI 1255349288 · CMS profile ID 11650

Allopathic & Osteopathic Physicians / Dermatology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 14; records 51–100 of 657 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255349288?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NEAL D BHATIA, NPI 1255349288, CMS profile ID 11650. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 14; records 51–100 of 657 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255349288?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NEAL D BHATIA, NPI 1255349288, CMS profile ID 11650. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 14; records 51–100 of 657 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255349288?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NEAL D BHATIA, NPI 1255349288, CMS profile ID 11650, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 14; records 51–100 of 657 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1255349288?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

657 matching records · $588,420.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 657 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 657.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $28.7012/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949597287 CMS
Journey Medical Corporation $65.7412/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924781487 CMS
LEO Pharma Inc. $21.2812/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200661 CMS
GENZYME CORPORATION $2,928.0012/07/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938842423 CMS
LEO Pharma Inc. $5,395.0012/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200653 CMS
LEO Pharma Inc. $4,565.0012/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200657 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.7512/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887761275 CMS
LEO Pharma Inc. $100.2312/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200641 CMS
LEO Pharma Inc. $197.7512/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200645 CMS
LEO Pharma Inc. $441.2012/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200649 CMS
PFIZER INC. $15.3212/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949584861 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $68.8812/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887761273 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $51.3312/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887761277 CMS
E.R. Squibb & Sons, L.L.C. $121.9012/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932718779 CMS
LEO Pharma Inc. $41.9512/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200637 CMS
ABBVIE INC. $14.3911/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890609531 CMS
LEO Pharma Inc. $114.0011/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200633 CMS
GENZYME CORPORATION $67.8111/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938842409 CMS
E.R. Squibb & Sons, L.L.C. $14.6511/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932718771 CMS
Amgen Inc. $17.6811/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939947753 CMS
Amgen Inc. $2.9911/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939947755 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $38.2211/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947510003 CMS
Regeneron Healthcare Solutions, Inc. $3,209.0011/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108803 CMS
Regeneron Healthcare Solutions, Inc. $7,487.0011/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108807 CMS
Regeneron Healthcare Solutions, Inc. $331.5011/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108811 CMS
Regeneron Healthcare Solutions, Inc. $3,209.0011/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108815 CMS
ABBVIE INC. $800.0011/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890609529 CMS
Incyte Corporation $14.9211/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943051559 CMS
Incyte Corporation $2.4511/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943051561 CMS
Regeneron Healthcare Solutions, Inc. $172.0011/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108783 CMS
Regeneron Healthcare Solutions, Inc. $148.0011/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108787 CMS
Regeneron Healthcare Solutions, Inc. $155.0011/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108791 CMS
Regeneron Healthcare Solutions, Inc. $160.0011/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108795 CMS
Regeneron Healthcare Solutions, Inc. $180.0711/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108799 CMS
Regeneron Healthcare Solutions, Inc. $191.8211/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108775 CMS
Regeneron Healthcare Solutions, Inc. $125.0011/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108779 CMS
E.R. Squibb & Sons, L.L.C. $6,215.0011/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932718793 CMS
E.R. Squibb & Sons, L.L.C. $5,015.0011/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932718829 CMS
GENZYME CORPORATION $77.5911/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938842393 CMS
Regeneron Healthcare Solutions, Inc. $15.4111/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108767 CMS
Regeneron Healthcare Solutions, Inc. $36.0811/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927108771 CMS
Sun Pharmaceutical Industries Inc. $54.4111/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947864312 CMS
LEO Pharma Inc. $2,075.0011/16/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200625 CMS
LEO Pharma Inc. $2,075.0011/16/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936200629 CMS
ABBVIE INC. $2,100.0011/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890609527 CMS
GENZYME CORPORATION $2,496.0011/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938842425 CMS
Almirall LLC $8.1611/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965163093 CMS
Novartis Pharmaceuticals Corporation $41.5711/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893531383 CMS
ABBVIE INC. $749.1911/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890609525 CMS
Almirall LLC $2,000.0011/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902842519 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $180,428.88 283
PY2020 $159,897.56 205
PY2021 $342,434.82 404
PY2022 $588,420.94 657
PY2023 $421,820.01 618
PY2024 $440,504.92 562
PY2025 $352,597.46 543

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $326,673.32 79
PY2024 Recipient $104.58 1
PY2024 Principal investigator $307,179.03 126
PY2023 Principal investigator $293,247.18 95
PY2022 Recipient $3,200.00 1
PY2022 Principal investigator $224,707.65 69
PY2021 Recipient $5,332.00 4
PY2021 Principal investigator $318,075.72 69
PY2020 Recipient $2,300.31 5
PY2020 Principal investigator $411,668.50 108
PY2019 Recipient $31,860.58 10
PY2019 Principal investigator $690,812.93 99

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $30,800.06 12/31/2025 Non-covered Recipient Entity
THERAPEUTICS CLINICAL RESEARCH
A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation No dispute reported 06/30/2026 1202533655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.00 12/25/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184280316
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,919.50 12/18/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434992
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 12/10/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289520
Principal investigator 1 ABBVIE INC. $1,105.46 12/08/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202529628
Principal investigator 1 ABBVIE INC. $5,062.50 12/05/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202529376
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,535.30 12/01/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289087
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 11/27/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo. No dispute reported 06/30/2026 1223288779
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,330.00 11/27/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo. No dispute reported 06/30/2026 1223288781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,000.00 11/27/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo. No dispute reported 06/30/2026 1223288783
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,835.00 11/20/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434987
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $518.70 11/07/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.97 11/06/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184257723
Principal investigator 1 ABBVIE INC. $750.00 11/04/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202520561
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,299.40 10/23/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434978
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 10/15/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286983
Principal investigator 1 SANOFI US SERVICES INC. $217.80 10/14/2025 Non-covered Recipient Entity
Tcr Medical Corporation
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226118900
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,383.90 10/09/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434974
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,429.58 10/08/2025 Non-covered Recipient Entity
THERAPEUTICS CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301699
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 10/03/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 10/03/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,495.70 10/01/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.81 09/18/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184240154
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 09/17/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285614
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,907.90 09/15/2025 Non-covered Recipient Entity
THERAPEUTICS CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190306977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 09/12/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 09/12/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285357
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,750.00 09/04/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434971
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,283.80 09/03/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $231.20 08/14/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184227713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $782.60 08/14/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184227715
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,233.85 08/13/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434967
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,499.65 08/12/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.37 08/04/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184223202
Principal investigator 1 Novartis Pharmaceuticals Corporation $293.50 08/01/2025 Non-covered Recipient Entity
THERAPEUTICS CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301701
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,816.80 08/01/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283771
Principal investigator 1 SANOFI US SERVICES INC. $4,050.00 07/21/2025 Non-covered Recipient Entity
Tcr Medical Corporation
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226118895
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,577.00 06/24/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.31 06/19/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184209027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.00 06/19/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209436
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,953.70 06/06/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280938
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,694.58 06/04/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280718
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,000.00 05/28/2025 Non-covered Recipient Entity
TCR Medical Corporation
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434953
Principal investigator 1 ABBVIE INC. $750.00 04/24/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202479320
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 04/16/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278130
Principal investigator 1 SANOFI US SERVICES INC. $12,500.00 04/14/2025 Non-covered Recipient Entity
Tcr Medical Corporation
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226118892
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 04/11/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277912
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 04/11/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277914
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 04/11/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277916
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 04/11/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $411.18 04/10/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184182880
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 04/02/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277530
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,784.60 04/02/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $121.35 03/27/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184180210
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,572.35 03/21/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276937
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 03/21/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,089.62 03/13/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184173820
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,129.10 03/05/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.60 02/27/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184156198
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,158.40 02/26/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275641
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,572.35 02/26/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275643
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 02/26/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275645
Principal investigator 1 Eli Lilly and Company $3,827.77 02/25/2025 Non-covered Recipient Entity
THERAPEUTICS CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187893188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.00 02/20/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155096
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,499.58 02/14/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275327
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $225.00 02/14/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275329
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 02/13/2025 Non-covered Recipient Entity
Tcr Medcl Corp.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175177387
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/13/2025 Non-covered Recipient Entity
Tcr Medcl Corp.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175177711
Principal investigator 1 Janssen Research & Development, LLC $800.00 02/13/2025 Non-covered Recipient Entity
Tcr Medcl Corp.
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175177747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $415.74 02/13/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184153978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,464.82 02/13/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184153980
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,128.10 02/05/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,065.40 02/03/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274677
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 02/03/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274679
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 02/03/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,913.21 01/30/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184151142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $198.00 01/16/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184147937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,859.67 01/16/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184147939
Principal investigator 1 Eli Lilly and Company $100,076.54 01/08/2025 Non-covered Recipient Entity
TCR MEDICAL CORPORATION
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187891250